Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants
Brain · 2023
DOI: 10.1093/brain/awad187 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Brain, 2023. Verfasst von Christopher J Record und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterized by progressive sensory and motor neuropathy with males affected more severely than females. Many reported GJB1 variants remain classified as variants of uncertain significance (VUS). In this large, international, multicentre study we prospectively collected demographic, clinical and genetic data on patients with CMT associated with GJB1 variants. Pathogenicity for each variant was defined using adapted American College of Medical Genetics criteria. Baseline and longitudinal analyses were conducted to study genotype-phenotype correlations, to calculate longitudinal change using the CMT Examination Score (CMTES), to compare males versus females, and pathogenic/likely pathogenic (P/LP) variants versus VUS. We present 387 patients from 295 families harbouring 154 variants in GJB1. Of these, 319 patients (82.4%) were deemed to have P/LP variants, 65 had VUS (16.8%) and three benign variants (0.8%; excluded from analysis); an increased proportion of patients with P/LP variants compared with using ClinVar’s classification (74.6%). Male patients (166/319, 52.0%, P/LP only) were more severely affected at baseline. Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline. Genotype-phenotype analysis suggested c.-17G>A produces the most severe phenotype of the five most common variants, and missense variants in the intracellular domain are less severe than other domains. Progression of disease was seen with increasing CMTES over time up to 8 years follow-up. Standard response mean (SRM), a measure of outcome responsiveness, peaked at 3 years with moderate responsiveness [change in CMTES (ΔCMTES) = 1.3 ± 2.6, P = 0.00016, SRM = 0.50]. Males and females progressed similarly up to 8 years, but baseline regression analysis suggested that over a longer period, females progress more slowly. Progression was most pronounced for mild phenotypes (CMTES = 0–7; 3-year ΔCMTES = 2.3 ± 2.5, P = 0.001, SRM = 0.90). Enhanced variant interpretation has yielded an increased proportion of GJB1 variants classified as P/LP and will aid future variant interpretation in this gene. Baseline and longitudinal analysis of this large cohort of CMTX1 patients describes the natural history of the disease including the rate of progression; CMTES showed moderate responsiveness for the whole group at 3 years and higher responsiveness for the mild group at 3, 4 and 5 years. These results have implications for patient selection for upcoming clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.
- Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
- Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
- Departments of Neurology and Neuroscience, John Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0PY, UK.
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
ORCID-Profile: Christopher J Record, Davide Pareyson, Chiara Pisciotta, Rita Horvath, Richard S Finkel, Stephan Zuchner, Mary M Reilly
Förderung
- NINDS NIH HHS
- Wellcome Trust
- Medical Research Council
- Department of Health
- The Inherited Neuropathies Consortium
- Rare Disease Clinical Research Network
- International Centre for Genomic Medicine in Neuromuscular Diseases
- National Institutes of Neurological Diseases and Stroke and office of Rare Diseases
Zitieren
APA
Record, C. J., Skorupinska, M., Laura, M., Rossor, A. M., Pareyson, D., Pisciotta, C., Feely, S. M. E., Lloyd, T. E., Horvath, R., Sadjadi, R., Herrmann, D. N., Li, J., Walk, D., Yum, S. W., Lewis, R. A., Day, J., Burns, J., Finkel, R. S., Saporta, M. A., …, & Inherited Neuropathies Consortium—Rare Disease Clinical Research Network (2023). Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants. Brain. https://doi.org/10.1093/brain/awad187
Vancouver
Record CJ, Skorupinska M, Laura M, Rossor AM, Pareyson D, Pisciotta C, et al. Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants. Brain. 2023. doi:10.1093/brain/awad187
BibTeX
@article{Record2023,
author = {Record, Christopher J and Skorupinska, Mariola and Laura, Matilde and Rossor, Alexander M and Pareyson, Davide and Pisciotta, Chiara and Feely, Shawna M E and Lloyd, Thomas E and Horvath, Rita and Sadjadi, Reza and Herrmann, David N and Li, Jun and Walk, David and Yum, Sabrina W and Lewis, Richard A and Day, John and Burns, Joshua and Finkel, Richard S and Saporta, Mario A and Ramchandren, Sindhu and Weiss, Michael D and Acsadi, Gyula and Fridman, Vera and Muntoni, Francesco and Poh, Roy and Polke, James M and Zuchner, Stephan and Shy, Michael E and Scherer, Steven S and Reilly, Mary M and Inherited Neuropathies Consortium—Rare Disease Clinical Research Network, Inherited Neuropathies Consortium—Rare Disease Clinical Research Network},
title = {Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awad187}
}
EUVIMED